|IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex.
|IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex.
|Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis.
|Isolation of full-length cDNA and chromosomal localization of human NF-kappaB modulator NEMO to Xq28.
|Role of adapter function in oncoprotein-mediated activation of NF-kappaB: human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma.
|Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti.
|cDNA cloning by amplification of circularized first strand cDNAs reveals non-IRE-regulated iron-responsive mRNAs.
|A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).
|Activation of IKKalpha and IKKbeta through their fusion with HTLV-I tax protein.
|Role of ikkgamma/nemo in assembly of the IkappaB kinase complex.
|Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.
|X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappa B signaling.
|Functional redundancy of the zinc fingers of A20 for inhibition of NF-kappaB activation and protein-protein interactions.
|CSN3 interacts with IKKgamma and inhibits TNF- but not IL-1-induced NF-kappaB activation.
|A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations.
|Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase.
|Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations.
|Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases.
|Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation.
|In vivo identification of inducible phosphoacceptors in the IKKgamma/NEMO subunit of human IkappaB kinase.
|The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
|Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress.
|Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.
|Complete sequencing and characterization of 21,243 full-length human cDNAs.
|ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of NFkappaB activation.
|The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation.
|The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.
|Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation.
|Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia.
|PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages.
|The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
|The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO.
|The DNA sequence of the human X chromosome.
|PIDD mediates NF-kappaB activation in response to DNA damage.
|Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.
|Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation.
|X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production.
|IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease.
|Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.
|Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti.
|Phosphorylation of serine 68 in the IkappaB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NF-kappaB activity.
|A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.
|Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347.
|Solution structure of NEMO zinc finger and impact of an anhidrotic ectodermal dysplasia with immunodeficiency-related point mutation.
|Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site.
|A quantitative atlas of mitotic phosphorylation.
|Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
|The zinc finger of NEMO is a functional ubiquitin-binding domain.
|Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation.
|Structural basis for recognition of diubiquitins by NEMO.
|Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3.
|DARPin-assisted crystallography of the CC2-LZ domain of NEMO reveals a coupling between dimerization and ubiquitin binding.
|A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response.
|Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
|NEMO gene mutations in Chinese patients with incontinentia pigmenti.
|Polyubiquitin conjugation to NEMO by tripartite motif protein 23 (TRIM23) is critical in antiviral defense.
|Initial characterization of the human central proteome.
|Linear ubiquitination prevents inflammation and regulates immune signalling.
|SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex.
|SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis.
|TRIM40 promotes neddylation of IKKgamma and is downregulated in gastrointestinal cancers.
|Polyubiquitin binding to ABIN1 is required to prevent autoimmunity.
|Direct, noncatalytic mechanism of IKK inhibition by A20.
|NLRP10 enhances Shigella-induced pro-inflammatory responses.
|IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.
|Identifying post-translational modifications of NEMO by tandem mass spectrometry after high affinity purification.
|An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
|Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease.
|TRAF family member-associated NF-kappaB activator (TANK) inhibits genotoxic nuclear factor kappaB activation by facilitating deubiquitinase USP10-dependent deubiquitination of TRAF6 ligase.
|IFIT5 positively regulates NF-kappaB signaling through synergizing the recruitment of IkappaB kinase (IKK) to TGF-beta-activated kinase 1 (TAK1).
|Molluscum contagiosum virus protein MC005 inhibits NF-kappaB activation by targeting NEMO-regulated IkappaB kinase activation.